secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2022-10-28T23:59:59+00:00
Accession:  0001171843-22-006866
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharma receives Nasdaq delisting notice for bid price below $1.00
------------------------------------------------------------------------

- Nasdaq notified Corvus on Oct 25, 2022 that its stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.
- Company has 180 calendar days, until April 24, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
- If non-compliance persists, Corvus may transfer to Nasdaq Capital Market and seek an additional 180-day grace period.
- Corvus may consider a reverse stock split or other options to cure the deficiency but no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322006866/0001171843-22-006866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322006866/f8k_102722.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-006866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer